Omnix Medical doses first patients in phase II trial of antimicrobial lead compound OMN6
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Subscribe To Our Newsletter & Stay Updated